Enzolytics Stock

Enzolytics FCF/Debt

The Free Cash Flow to Debt Ratio of Enzolytics (ENZC) as of Aug 18, 2026 is -25.74 %.

FCF/Debt

-25.74 %

Last updated:

Free Cash Flow to Debt Ratio of Enzolytics is 2026 -25.74 % . Free Cash Flow to Debt Ratio of Enzolytics was 2025 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Enzolytics Stock analysis

What does Enzolytics do? Enzolytics Inc is an innovative biotechnology company specializing in the development of effective therapies for combating infectious diseases and cancer. Enzolytics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enzolytics stock

Free Cash Flow to Debt Ratio of Enzolytics is -25.74 % in 2026.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Enzolytics since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Enzolytics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Enzolytics

All Key Metrics — Enzolytics